At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
OZEM Roundhill GLP-1 & Weight Loss ETF
Trading 11-09 10:40:59 EST
31.50
+0.61
+1.98%
High31.50Low31.22Vol836.00
Open31.22D1 Closing30.89Amplitude0.91%
Mkt Cap57.65MTradable Cap57.65MTotal Shares1.83M
T/O26.17KT/O Rate0.05%Tradable Shares1.83M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Eli Lilly Stock (LLY) Rises After Canada Approves Public Reimbursement of Its Alzheimer’s Drug
TIPRANKS  ·  24 minutes ago
Eli Lilly Stock (LLY) Rises After Canada Approves Public Reimbursement of Its Alzheimer’s Drug
Lilly's Weight-Loss Pill Meets Main Goal in Late-Stage Sleep Apnea Study
Reuters  ·  22:39
Lilly's Weight-Loss Pill Meets Main Goal in Late-Stage Sleep Apnea Study
Eli Lilly announces ‘positive’ results from Phase 3 study of Foundayo
TIPRANKS  ·  22:35
Eli Lilly announces ‘positive’ results from Phase 3 study of Foundayo
Eli Lilly's Foundayo Reduces Sleep Apnea Severity by up to 44% in Phase 3 Trial
Reuters  ·  22:31
Eli Lilly's Foundayo Reduces Sleep Apnea Severity by up to 44% in Phase 3 Trial
Eli Lilly: at 52 Weeks, Foundayo Met Primary Endpoint
THOMSON REUTERS  ·  22:30
Eli Lilly: at 52 Weeks, Foundayo Met Primary Endpoint
Lilly's Foundayo (Orforglipron) Significantly Reduced Obstructive Sleep Apnea Severity, Reinforcing Its Potential to Improve Health Beyond Weight Loss
THOMSON REUTERS  ·  22:30
Lilly's Foundayo (Orforglipron) Significantly Reduced Obstructive Sleep Apnea Severity, Reinforcing Its Potential to Improve Health Beyond Weight Loss
Eli Lilly - Foundayo Reduces Breathing Interruptions by up to 44%, 32% Achieve Remission or Mild Disease
THOMSON REUTERS  ·  22:30
Eli Lilly - Foundayo Reduces Breathing Interruptions by up to 44%, 32% Achieve Remission or Mild Disease
Eli Lilly: Overall Safety & Tolerability Profile of Foundayo was Generally Consistent with Previous Trials in Achieve and Attain Programs
THOMSON REUTERS  ·  22:30
Eli Lilly: Overall Safety & Tolerability Profile of Foundayo was Generally Consistent with Previous Trials in Achieve and Attain Programs
Eli Lilly - Foundayo Significantly Reduces Apnea-Hypopnea Index and Improves Weight and Cardiovascular Risk Factors at 52 Weeks
THOMSON REUTERS  ·  22:30
Eli Lilly - Foundayo Significantly Reduces Apnea-Hypopnea Index and Improves Weight and Cardiovascular Risk Factors at 52 Weeks
Viking Therapeutics (VKTX) Moved, What Is Drawing Attention Now?
Simply Wall St.  ·  22:24
Viking Therapeutics (VKTX) Moved, What Is Drawing Attention Now?
Kailera Therapeutics Inc : Canaccord Genuity Initiates Coverage with Buy Rating; Price Target $44
THOMSON REUTERS  ·  22:06
Kailera Therapeutics Inc : Canaccord Genuity Initiates Coverage with Buy Rating; Price Target $44
Sector Update: Healthcare
MT Newswires Live  ·  22:03
Sector Update: Healthcare
Viking Therapeutics Announces Two Vk2735 Poster Presentations at ObesityWeek
Reuters  ·  20:12
Viking Therapeutics Announces Two Vk2735 Poster Presentations at ObesityWeek
US Stocks on the MOVE-Nvidia, Genmab, Eli Lilly
Reuters  ·  20:08
US Stocks on the MOVE-Nvidia, Genmab, Eli Lilly
A 17-Month High in the Dollar, and the Ten ADRhedged™ ETFs That Held Their Ground Against It
TIPRANKS  ·  20:00
A 17-Month High in the Dollar, and the Ten ADRhedged™ ETFs That Held Their Ground Against It
Jefferies Lifts Lilly PT, Says Ex-US GLP-1 Opportunity Underestimated
Reuters  ·  19:43
Jefferies Lifts Lilly PT, Says Ex-US GLP-1 Opportunity Underestimated
Eli Lilly : Jefferies Raises Target Price to $1700 from $1610
THOMSON REUTERS  ·  19:36
Eli Lilly : Jefferies Raises Target Price to $1700 from $1610
Novo Nordisk Wegovy Showed Better Liver Data in Patient Group
MT Newswires Live  ·  18:12
Novo Nordisk Wegovy Showed Better Liver Data in Patient Group
Pfizer (PFE) Lifts Guidance Following Pipeline Wins While Fair Value Looks Near Reach
Simply Wall St.  ·  12:47
Pfizer (PFE) Lifts Guidance Following Pipeline Wins While Fair Value Looks Near Reach
3 Biotech Stocks With Revenue Growth Up To 30%
Simply Wall St.  ·  01:29
3 Biotech Stocks With Revenue Growth Up To 30%

Introduction

Company Name.
Roundhill GLP-1 & Weight Loss ETF
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Issue price:
--